FAS mRNA expression in the liver is significantly higher in patients with NAFL/NASH than that in normal subjects.90 In a phase 2 clinical trial, administration of TVB-2640, a FAS inhibitor, showed promising results in adult patients with NASH with ≥8% liver fat and liver fibrosis (NCT03938246).91 TVB-2640 reduced liver fat by 9.6% in the 25 mg cohort and 28.1% in the 50 mg cohort from baseline compared to 4.5% increase in liver fat in the placebo cohort. Here, FAS is linked to metabolic dysfunction-associated steatohepatitis.